NICE reversed its prior restriction for dapagliflozin in low UACR CKD, a decision originally based on limited data for a high-risk subgroup (non-T2D, low uACR). This shift demonstrates growing trust in high-quality RWE research to resolve uncertainty where RCT data are limited or lacking.